Prevalence of treated patients with Alzheimer's disease : current trends and COVID-19 impact
Olazarán, Javier (Hospital General Universitario Gregorio Marañón)
Carnero-Pardo, Cristóbal (FIDYAN Neurocenter)
Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau)
Sánchez-Juan, Pascual (Fundación CIEN (Centro de Investigación de Enfermedades Neurológicas))
García-Ribas, Guillermo (Hospital Universitario Ramón y Cajal (Madrid))
Viñuela, Félix (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Martínez-Lage, Pablo (Fundación CITA-Alzhéimer Fundazioa (San Sebastián, País Basc))
Boada, Mercè (Universitat Internacional de Catalunya)
Universitat Autònoma de Barcelona

Data:	2023
Resum:	There are few updated studies on the prevalence and management of Alzheimer's disease (AD), which could be underdiagnosed or undertreated. The COVID-19 pandemic may have worsened the deficiencies in the diagnosis and treatment of these patients. Electronic medical records (EMR) offer an opportunity to assess the impact and management of medical processes and contingencies in the population. To estimate AD prevalence in Spain over a 6-year period, based on treated patients, according to usual clinical practice. Additionally, to describe the management of AD-treated patients and the evolution of that treatment during the 2020 COVID-19 pandemic. Retrospective study using the Spanish IQVIA EMR database. Patients treated with donepezil, galantamine, rivastigmine, and/or memantine were included in the study. Annual AD prevalence (2015-2020) was estimated and extrapolated to the national population level. Most frequent treatments and involved specialties were described. To assess the effect of COVID-19, the incidence of new AD cases in 2020 was calculated and compared with newly diagnosed cases in 2019. Crude AD prevalence (2015-2020) was estimated at 760. 5 per 100,000 inhabitants, and age-standardized prevalence (2020) was 664. 6 (male 595. 7, female 711. 0). Monotherapy was the most frequent way to treat AD (86. 2%), in comparison with dual therapy (13. 8%); rivastigmine was the most prescribed treatment (37. 3%), followed by memantine (36. 4%) and donepezil (33. 0%). Rivastigmine was also the most utilized medication in newly treated patients (46. 7%), followed by donepezil (29. 8%), although donepezil persistence was longer (22. 5 vs. 20. 6 months). Overall, donepezil 10 mg, rivastigmine 9. 5 mg, and memantine 20 mg were the most prescribed presentations. The incidence rate of AD decreased from 148. 1/100,000 (95% confidence interval [CI] 147. 0-149. 2) in 2019 to 118. 4/100,000 (95% CI 117. 5-119. 4) in 2020. Conclusions: The obtained prevalence of AD-treated patients was consistent with previous face-to-face studies. In contrast with previous studies, rivastigmine, rather than donepezil, was the most frequent treatment. A decrease in the incidence of AD-treated patients was observed during 2020 in comparison with 2019, presumably due to the significant impact of the COVID-19 pandemic on both diagnosis and treatment. EMR databases emerge as valuable tools to monitor in real time the incidence and management of medical conditions in the population, as well as to assess the health impact of global contingencies and interventions.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Alzheimer disease ; Cholinesterase inhibitors ; Incidence ; Memantine ; Prevalence ; Spain ; Treatment
Publicat a:	Alzheimer's research & therapy, Vol. 15 Núm. 1 (december 2023) , p. 130, ISSN 1758-9193

DOI: 10.1186/s13195-023-01271-0
PMID: 37537656

13 p, 1.4 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats